Noble Romans (NROM) EBITDA (2010 - 2025)

Noble Romans' EBITDA history runs 15 years deep, the most recent figure standing at $170788.0 for Q4 2025.

• On a quarterly basis, EBITDA rose 150.12% year-over-year to $170788.0 in Q4 2025; TTM through Dec 2025 was $2.4 million, a 63.08% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, up 63.08% from the prior year.
• EBITDA was $170788.0 for Q4 2025 at Noble Romans, down from $819065.0 in the prior quarter.
• Over the last five years, EBITDA for NROM reached as high as $1.5 million in Q1 2023 and fell as low as -$395.0 in Q4 2022.
• A 5-year average of $499615.0 and a median of $428101.5 in 2021 frame the typical range for EBITDA.
• The widest annual swing landed in 2022, when EBITDA sank 272.64%; it then soared 176208.61% in 2023.
• Tracing NROM's EBITDA over 5 years: stood at -$106.0 in 2021, then sank by 272.64% to -$395.0 in 2022, then soared by 176208.61% to $695629.0 in 2023, then slumped by 90.18% to $68282.0 in 2024, then surged by 150.12% to $170788.0 in 2025.
• According to Business Quant data, EBITDA over the past three periods registered $170788.0, $819065.0, and $913999.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.